73

Oncology
Prevention and treatment of tumors, and caring for cancer patients.
Sub Categories on Oncology
Latest Articles
Protective mutation shown to impair esophagus tumor growth

Protective mutation shown to impair esophagus tumor growth

byWellcome Trust Sanger InstituteDifferentiation and homeostasis in aged Notch1 mutant mouse tissue. a, YFPCreNotch1flox/floxmice were induced at high dose so mutant cells rapidly covered

Protective mutation shown to impair esophagus tumor growth

byWellcome Trust Sanger InstituteDifferentiation and homeostasis in aged Notch1 mutant mouse tissue. a, YFPCreNotch1flox/floxmice were induced at high dose so mutant cells rapidly covered
Research collaboration reveals promising drug candidate for treatment of blood cancers

Research collaboration reveals promising drug candidate for treatment of blood cancers

by Children's Cancer Institute AustraliaCredit: CC0 Public DomainToday, OncoTartis, Inc. and Children's Cancer Institute jointly announced the publication of two research manuscripts in a lead

Research collaboration reveals promising drug candidate for treatment of blood cancers

by Children's Cancer Institute AustraliaCredit: CC0 Public DomainToday, OncoTartis, Inc. and Children's Cancer Institute jointly announced the publication of two research manuscripts in a lead
Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainPatients with cancers that are driven by certain mutations occurring in response to DNA damage can be safe

Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainPatients with cancers that are driven by certain mutations occurring in response to DNA damage can be safe
New technology in recent clinical study aims toward earlier detection of hepatocellular carcinoma

New technology in recent clinical study aims toward earlier detection of hepatocellular carcinoma

byUniversity of California, Los AngelesCredit: Pixabay/CC0 Public DomainPrimary liver cancer, the third-leading cause of cancer-related death worldwide, takes more than 30,000 lives in the Unite

New technology in recent clinical study aims toward earlier detection of hepatocellular carcinoma

byUniversity of California, Los AngelesCredit: Pixabay/CC0 Public DomainPrimary liver cancer, the third-leading cause of cancer-related death worldwide, takes more than 30,000 lives in the Unite
Sub-lobar surgery for peripheral non-small cell lung cancer non-inferior to lobectomy

Sub-lobar surgery for peripheral non-small cell lung cancer non-inferior to lobectomy

by International Association for the Study of Lung CancerCancer cell during cell division. Credit: National Institutes of HealthA large international study of patients with non-small cell lung cancer

Sub-lobar surgery for peripheral non-small cell lung cancer non-inferior to lobectomy

by International Association for the Study of Lung CancerCancer cell during cell division. Credit: National Institutes of HealthA large international study of patients with non-small cell lung cancer
Moderna's experimental cancer vaccine treats but doesn't prevent melanoma—a biochemist explains how it works

Moderna's experimental cancer vaccine treats but doesn't prevent melanoma—a biochemist explains how it works

by Mark R. O'Brian,The ConversationCredit: Pixabay/CC0 Public DomainMediaoutletshave reported the encouraging findings of clinical trials for a new experimental vaccine developed

Moderna's experimental cancer vaccine treats but doesn't prevent melanoma—a biochemist explains how it works

by Mark R. O'Brian,The ConversationCredit: Pixabay/CC0 Public DomainMediaoutletshave reported the encouraging findings of clinical trials for a new experimental vaccine developed
Study identifies genetic cause for some brain tumors

Study identifies genetic cause for some brain tumors

Study identifies genetic cause for some brain tumorsby Olivia Dimmer,Northwestern UniversityMultiplex immunofluorescence staining and imaging using the COMET system platform on a human meningiom

Study identifies genetic cause for some brain tumors

Study identifies genetic cause for some brain tumorsby Olivia Dimmer,Northwestern UniversityMultiplex immunofluorescence staining and imaging using the COMET system platform on a human meningiom
B cells linked to effective cancer immunotherapy

B cells linked to effective cancer immunotherapy

by Göran B Jönsson,Lund UniversityImmunofluorescence analysis of a melanoma tumor showing that B cells in B cell clusters express CXCR5, a marker for tertiary lymphoid structures. Credit: Göran

B cells linked to effective cancer immunotherapy

by Göran B Jönsson,Lund UniversityImmunofluorescence analysis of a melanoma tumor showing that B cells in B cell clusters express CXCR5, a marker for tertiary lymphoid structures. Credit: Göran
Acute leukemia patients treated with common therapy have increased risk for heart failure

Acute leukemia patients treated with common therapy have increased risk for heart failure

byPerelman School of Medicine at the University of PennsylvaniaPatients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who are treated with anthracyclines are at a heigh

Acute leukemia patients treated with common therapy have increased risk for heart failure

byPerelman School of Medicine at the University of PennsylvaniaPatients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who are treated with anthracyclines are at a heigh
Marker for therapy response in acute myeloid leukemia identified

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t